Kura Oncology to Present New Data Supporting Combination of KO-2806 with KRAS G12C and Pan-RAS Inhibitors Oct 23, 2024 07:30AM
Acute Myeloid Leukemia is on the Rise as Biotechs Race to Develop Groundbreaking Therapies Jun 17, 2024 09:00AM
Kura Oncology (KURA) and Mirati Therapeutics (MRTX) Enter Collaboration and Supply Agreement to for KO-2806 and Adagrasib in KRAS-Mutated NSCLC Nov 2, 2023 07:31AM
Kura Oncology and Mirati Therapeutics Enter into Clinical Collaboration and Supply Agreement to Evaluate KO-2806 and Adagrasib in KRASᴳ¹²ᶜ-Mutated NSCLC Nov 2, 2023 07:30AM
Kura Oncology to Participate in Three Upcoming Investor Conferences Oct 30, 2023 07:30AM


Oct 26, 2023 04:05PM Kura Oncology to Report Third Quarter 2023 Financial Results
Oct 19, 2023 07:30AM Kura Oncology Announces First Patient Dosed in FIT-001 Trial of Next-Generation Farnesyl Transferase Inhibitor KO-2806
Oct 17, 2023 04:10PM Kura Oncology (KURA) Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC
Oct 17, 2023 04:05PM Kura Oncology Announces Positive Results from Registration-Directed Study of Tipifarnib in Patients with HRAS Mutant HNSCC
Oct 4, 2023 07:30AM Kura Oncology Announces Three Presentations at AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Sep 28, 2023 07:30AM Kura Oncology Reports Preclinical Data Showing Ability of KO-2806 to Enhance Antitumor Activity of KRASᴳ¹²ᶜ Inhibitors in Non-Small Cell Lung Cancer
Sep 19, 2023 07:30AM Kura Oncology to Participate in Cantor Global Healthcare Conference 2023
Aug 14, 2023 07:30AM Kura Oncology Appoints Brian Powl as Chief Commercial Officer
Aug 3, 2023 04:05PM Kura Oncology Reports Second Quarter 2023 Financial Results
Aug 31, 2021 07:00AM PepGen Announces New Additions to Leadership Team and Board of Directors